bio_5

Discover how Contract Research Organizations (CROs) accelerate therapeutic development through specialized expertise, cost-effective solutions, scalability, and biotech innovation.

In the realm of combating bacterial infections and antimicrobial resistance, antibodies are beginning to stand out as a therapy with innovative strategies and engineering methods continually being published. This month’s trend will focus on the developments in ‘antibiotic antibodies’, antibody-antibiotic conjugates, and antibody antimicrobials, which are particularly important for immunocompromised patients.

Entering into the new year, the popularity of antibody-drug conjugates (ADCs) in the biopharma industry shows no signs of slowing down. In 2023, there were a record number of licensing partnerships in the ADC space, particularly Merck’s $22 billion deal with Daiichi Sankyo, Inc.

The BIO International Convention 2024, scheduled for June 3-6 in San Diego, CA, is set to be an exciting event for the biotechnology industry. Biointron is excited to be a part of this prestigious event. We invite you to visit our booth, number 1512.

We are thrilled to announce Biointron's participation in the 20th Annual PEGS Boston (The Protein Engineering Summit), happening from May 13-17, 2024, in Boston, MA. Organized by CHI, this summit is the epitome of innovation in protein and antibody engineering, a field where Biointron has continually demonstrated its leadership.

Biointron invites you to join us at BIO KOREA 2024! Bio Krea has been a premier international convention for biotech companies and industry leaders. Scheduled from May 8th to 10th, 2024, at COEX in Seoul, this event promises to be a nexus of innovation in the health industry.

Biointron is excited to invite you to Biologics 2024, scheduled from 13th to 15th March in London, UK. This event, Europe's leading platform for biologics discovery and development, promises to be a pivotal gathering for industry experts and thought leaders.

The Antibody Therapeutics Xchange 2024, set to take place in San Diego on February 26th, is a highly anticipated event in the world of antibody therapeutics, and Biointron is proud to be a part of it.

Biointron has developed our own CHOK1-Fut8KO expression platform for afucosylated antibodies.

Biointron established a single-B cell antibody discovery platform based on microfluidic technology. Combined with our proprietary fast antibody expression platform, it has been proven to be fast and efficient in many projects.

Biointron has developed a successful method for discovering alpaca VHH for over 200 projects, using flexible immunization strategies and a robust phage display screening platform.

The Biointron team is excited to announce our participation in the Festival of Biologics 2024.

Biointron is excited to announce our participation in the upcoming AACR (American Association for Cancer Research) 2024 Annual Meeting.

Biointron is thrilled to announce our participation in the upcoming 23rd Annual PepTalk conference, scheduled for January 16-19 in San Diego.

Research into treatments for Alzheimer's disease (AD) has reached impressive milestones this year.